Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-19

Clinical Trial Update: Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Zevalin regimen versus no further treatment in diffuse large B-cell lymphoma was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Lymphoma, Large Cell, Diffuse | Phase 3 | Status: TERMINATED | Results posted: 2022-01-19